Literature DB >> 25744636

Surgical and endoscopic management of high grade dysplasia and early oesophageal adenocarcinoma.

Philip A Le Page1, Pras P Velu2, Ian D Penman3, Graeme W Couper2, Simon Paterson-Brown2, Peter J Lamb2.   

Abstract

BACKGROUND: The introduction of endoscopic techniques has led to debate about optimal management of early oesophageal adenocarcinoma. The aim was to evaluate patient selection and outcomes for endoscopic or surgical treatment at a tertiary referral centre.
METHODS: A prospectively collected database of consecutive patients staged with high-grade dysplasia (HGD) or T1 oesophageal adenocarcinoma treated with curative intent between 2005 and 2013 was undertaken. All patients were discussed at the multidisciplinary team meeting. Surgical treatment was by thoracoscopic assisted or standard/laparoscopic assisted Ivor Lewis oesophagectomy. Endoscopic treatment was a structured programme of endoscopic mucosal resection (EMR) and/or radiofrequency ablation (RFA). Outcomes included treatment variables, recurrence and complications.
RESULTS: 83 patients treated; 50 with endoscopic therapy (EMR only-4, EMR then RFA-22, RFA only-24) and 38 by surgery (33 straight to surgery and 5 following EMR). Median age (67) and mean follow-up (21 months) were similar. HGD was more common in the endoscopic group (32/50, 64%, vs.3/33, 9%, p = 0.0001). Significant complications were more common following surgery (13/38, 34%, vs. 1/50, 2%, p = 0.0001). There were two in-hospital deaths following oesophagectomy (1 open, 1 thoracoscopic). Endoscopic treatment beyond 12 months for persisting HGD/intramucosal disease was required in 2 patients. Recurrence of HGD/invasive cancer was diagnosed in 2/36 (5.6%, T1a recurrence) of endoscopic and 1/38 (2.6%, T2N0 - subsequent hepatic metastases) surgical patients.
CONCLUSION: A management algorithm including both endoscopic treatment and oesophagectomy provides optimal outcome for these patients. Due to additional morbidity of surgery, endoscopic treatment is appropriate first-line treatment. Crown
Copyright © 2015. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Barrett's oesophagus; Endoscopic ablation; Endoscopic mucosal resection; Oesophageal cancer; Oesophagectomy

Mesh:

Year:  2015        PMID: 25744636     DOI: 10.1016/j.surge.2015.01.001

Source DB:  PubMed          Journal:  Surgeon        ISSN: 1479-666X            Impact factor:   2.392


  5 in total

1.  Recurrence of Barrett's Esophagus is Rare Following Endoscopic Eradication Therapy Coupled With Effective Reflux Control.

Authors:  Srinadh Komanduri; Peter J Kahrilas; Kumar Krishnan; Tim McGorisk; Kiran Bidari; David Grande; Laurie Keefer; John Pandolfino
Journal:  Am J Gastroenterol       Date:  2017-02-14       Impact factor: 10.864

2.  Prognosis of patients with superficial T1 esophageal cancer who underwent endoscopic resection before esophagectomy-A propensity score-matched comparison.

Authors:  Patrick Sven Plum; Arnulf Heinrich Hölscher; Kristin Pacheco Godoy; Henner Schmidt; Felix Berlth; Seung-Hun Chon; Hakan Alakus; Elfriede Bollschweiler
Journal:  Surg Endosc       Date:  2018-03-13       Impact factor: 4.584

Review 3.  Outcomes of Radiofrequency Ablation for Dysplastic Barrett's Esophagus: A Comprehensive Review.

Authors:  Carmelo Luigiano; Giuseppe Iabichino; Leonardo Henry Eusebi; Monica Arena; Pierluigi Consolo; Carmela Morace; Enrico Opocher; Benedetto Mangiavillano
Journal:  Gastroenterol Res Pract       Date:  2016-12-14       Impact factor: 2.260

4.  Comparison of Long-Term Survival Between cT1N0 Stage Esophageal Cancer Patients Receiving Endoscopic Dissection and Esophagectomy: A Meta-Analysis.

Authors:  Wei Lu; Peng Li; Wu Wen; Yi Jian
Journal:  Front Surg       Date:  2022-05-06

5.  Recurrence of intestinal metaplasia and early neoplasia after endoscopic eradication therapy for Barrett's esophagus: a systematic review and meta-analysis.

Authors:  Larissa L Fujii-Lau; Birtukan Cinnor; Nicholas Shaheen; Srinivas Gaddam; Srinadh Komanduri; V Raman Muthusamy; Ananya Das; Robert Wilson; Violette C Simon; Vladimir Kushnir; Daniel Mullady; Steven A Edmundowicz; Dayna S Early; Sachin Wani
Journal:  Endosc Int Open       Date:  2017-05-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.